BE2017C067I2 - - Google Patents

Download PDF

Info

Publication number: BE2017C067I2
Authority: BE; Belgium
Prior art keywords: warm; treatment; allergy; mastocytosis; angioedema
Prior art date: 2003-06-18

Application number

BE2017C067C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-18

Filing date

2017-12-19

Publication date

2023-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C067(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-19 Application filed by Novartis Ag filed Critical Novartis Ag

2023-08-09 Publication of BE2017C067I2 publication Critical patent/BE2017C067I2/fr

Links

241001465754 Metazoa Species 0.000 abstract 2
208000028185 Angioedema Diseases 0.000 abstract 1
206010006473 Bronchopulmonary aspergillosis Diseases 0.000 abstract 1
206010012434 Dermatitis allergic Diseases 0.000 abstract 1
206010013700 Drug hypersensitivity Diseases 0.000 abstract 1
208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
206010016946 Food allergy Diseases 0.000 abstract 1
208000004430 Pulmonary Aspergillosis Diseases 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
208000034972 Sudden Infant Death Diseases 0.000 abstract 1
206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
208000024780 Urticaria Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
201000008937 atopic dermatitis Diseases 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
201000005311 drug allergy Diseases 0.000 abstract 1
235000020932 food allergy Nutrition 0.000 abstract 1
208000008585 mastocytosis Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
238000002638 palliative care Methods 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BE2017C067C 2003-06-18 2017-12-19 BE2017C067I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47957503P	2003-06-18	2003-06-18
PCT/EP2004/006562 WO2004112794A2 (fr)	2003-06-18	2004-06-17	Nouvelle utilisation de derives de staurosporine
EP04740016A EP1638574B1 (fr)	2003-06-18	2004-06-17	Nouvelle utilisation de derives de staurosporine

Publications (1)

Publication Number	Publication Date
BE2017C067I2 true BE2017C067I2 (fr)	2023-08-09

Family

ID=33539193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2017C067C BE2017C067I2 (fr)	2003-06-18	2017-12-19

Country Status (23)

Country	Link
US (2)	US8575146B2 (fr)
EP (1)	EP1638574B1 (fr)
JP (2)	JP5057780B2 (fr)
CN (2)	CN100457111C (fr)
AT (1)	ATE464052T1 (fr)
AU (1)	AU2004248909B2 (fr)
BE (1)	BE2017C067I2 (fr)
BR (1)	BRPI0411563B8 (fr)
CA (2)	CA2785950A1 (fr)
CY (2)	CY1110179T1 (fr)
DE (1)	DE602004026578D1 (fr)
DK (1)	DK1638574T3 (fr)
ES (1)	ES2344700T3 (fr)
FR (1)	FR17C1063I2 (fr)
HU (1)	HUS000503I2 (fr)
LU (1)	LUC00055I9 (fr)
MX (1)	MXPA05013722A (fr)
NL (1)	NL300917I2 (fr)
PL (1)	PL1638574T3 (fr)
PT (1)	PT1638574E (fr)
SI (1)	SI1638574T1 (fr)
TW (1)	TWI324604B (fr)
WO (1)	WO2004112794A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
JP4762150B2 (ja)	2003-11-18	2011-08-31	ノバルティスアーゲー	Ｋｉｔの変異体の阻害剤
WO2005115385A1 (fr) *	2004-05-24	2005-12-08	Ab Science	Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
AU2005274852B2 (en) *	2004-07-19	2011-12-08	The Johns Hopkins University	FLT3 inhibitors for immune suppression
MX2007001155A (es) *	2004-07-29	2007-08-14	Creabilis Therapeutics Spa	Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
CN101171013A (zh) *	2005-05-02	2008-04-30	诺瓦提斯公司	嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
DE602006013826D1 (de) *	2005-07-20	2010-06-02	Peter Valent	Zusammensetzungen zur behandlung von systemischer mastocytose
CA2629478C (fr) *	2005-11-14	2013-10-15	Universitat Zurich	Derives de la staurosporine utilisables dans le rhabdomyosarcome alveolaire
WO2009092442A1 (fr) *	2008-01-23	2009-07-30	Universidad De Barcelona	Traitement de l'hypertension portale et d'états apparentés par une inhibition combinée des voies de signalisation de vegf et pdgf
EP2637650A2 (fr) *	2010-11-10	2013-09-18	National Jewish Health	Procédés de test d'états allergiques
AU2019374142A1 (en)	2018-11-01	2021-05-27	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
US11325978B2 (en) *	2018-11-06	2022-05-10	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Compositions and methods for treating beta-globinopathies
US11839619B2 (en) *	2019-09-16	2023-12-12	The Regents Of The University Of California	Methods for treatment of pediatric systemic mastocytosis
KR102805013B1 (ko) *	2022-03-15	2025-05-09	국립해양생물자원관	스트렙토마이세스 속 snc087 균주 또는 이로부터 분리한 스타우로스포린을 유효성분으로 포함하는 비용종 예방 또는 치료용 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4639455A (en) *	1984-10-02	1987-01-27	Key Pharmaceuticals, Inc.	Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US5093330A (en) *	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (fr) *	1990-08-07	2002-02-26	Peter D. Davis	Pyrroles substitues
DE69229490T2 (de) *	1991-05-09	2000-02-17	Neurim Pharmaceuticals (1991) Ltd., Tel Aviv	Melatonin enthaltende Arzneimittel
AR004480A1 (es) *	1995-04-06	1998-12-16	Amico Derin C D	Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US6184217B1 (en) *	1996-06-25	2001-02-06	Cephalon, Inc.	Use of K-252a derivative
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
WO1999062537A1 (fr)	1998-06-04	1999-12-09	The Rockefeller University	Procedes et agents permettant la modulation de la reponse immunitaire et de l'inflammation par modulation des proteines membranaires des monocytes et des cellules dendritiques
GB9903547D0 (en) *	1999-02-16	1999-04-07	Novartis Ag	Organic compounds
CA2431187A1 (fr)	2000-12-08	2002-06-13	Ortho-Mcneil Pharmaceutical, Inc.	Composes macro-heterocyliques utilises comme inhibiteurs de kinase
GB0108606D0 (en)	2001-04-05	2001-05-23	Novartis Ag	Organic compounds
DE60227709D1 (de) *	2001-06-29	2008-08-28	Ab Science	Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
CN101703509A (zh) *	2001-10-30	2010-05-12	诺瓦提斯公司	作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
EP1645286A1 (fr) *	2003-04-18	2006-04-12	Kyowa Hakko Kogyo Co., Ltd.	Medicament pour la regeneration des nerfs
US20070037882A1 (en) *	2003-04-22	2007-02-15	Astellas Pharma Inc.	Remedy for cerebral neurodegenerative diseases using ppar agonist
TWI324604B (en) *	2003-06-18	2010-05-11	Novartis Ag	New use of staurosporine derivatives
JP4762150B2 (ja)	2003-11-18	2011-08-31	ノバルティスアーゲー	Ｋｉｔの変異体の阻害剤

2004
- 2004-06-16 TW TW093117368A patent/TWI324604B/zh active
- 2004-06-17 DE DE602004026578T patent/DE602004026578D1/de not_active Expired - Lifetime
- 2004-06-17 JP JP2006515982A patent/JP5057780B2/ja not_active Expired - Lifetime
- 2004-06-17 AT AT04740016T patent/ATE464052T1/de active
- 2004-06-17 CA CA2785950A patent/CA2785950A1/fr not_active Abandoned
- 2004-06-17 PT PT04740016T patent/PT1638574E/pt unknown
- 2004-06-17 AU AU2004248909A patent/AU2004248909B2/en not_active Expired
- 2004-06-17 MX MXPA05013722A patent/MXPA05013722A/es active IP Right Grant
- 2004-06-17 SI SI200431450T patent/SI1638574T1/sl unknown
- 2004-06-17 CA CA2527703A patent/CA2527703C/fr not_active Expired - Lifetime
- 2004-06-17 CN CNB2004800168219A patent/CN100457111C/zh not_active Expired - Lifetime
- 2004-06-17 ES ES04740016T patent/ES2344700T3/es not_active Expired - Lifetime
- 2004-06-17 DK DK04740016.3T patent/DK1638574T3/da active
- 2004-06-17 BR BRPI0411563A patent/BRPI0411563B8/pt not_active IP Right Cessation
- 2004-06-17 US US10/560,669 patent/US8575146B2/en active Active
- 2004-06-17 PL PL04740016T patent/PL1638574T3/pl unknown
- 2004-06-17 WO PCT/EP2004/006562 patent/WO2004112794A2/fr not_active Ceased
- 2004-06-17 CN CNA2007101658371A patent/CN101164539A/zh active Pending
- 2004-06-17 EP EP04740016A patent/EP1638574B1/fr not_active Expired - Lifetime
2010
- 2010-07-06 CY CY20101100627T patent/CY1110179T1/el unknown
2012
- 2012-04-26 JP JP2012101493A patent/JP2012144572A/ja active Pending
2013
- 2013-06-27 US US13/929,438 patent/US20130289018A1/en not_active Abandoned
2017
- 2017-12-07 NL NL300917C patent/NL300917I2/nl unknown
- 2017-12-12 LU LU00055C patent/LUC00055I9/fr unknown
- 2017-12-14 HU HUS1700053C patent/HUS000503I2/hu unknown
- 2017-12-19 BE BE2017C067C patent/BE2017C067I2/fr unknown
- 2017-12-22 CY CY2017048C patent/CY2017048I1/el unknown
- 2017-12-28 FR FR17C1063C patent/FR17C1063I2/fr active Active

Also Published As

Publication number	Publication date
CN1805749A (zh)	2006-07-19
FR17C1063I2 (fr)	2019-05-03
CY2017048I2 (el)	2018-09-05
JP2012144572A (ja)	2012-08-02
US8575146B2 (en)	2013-11-05
HUS1700053I1 (hu)	2018-01-29
JP2006527727A (ja)	2006-12-07
BRPI0411563B8 (pt)	2021-05-25
JP5057780B2 (ja)	2012-10-24
PT1638574E (pt)	2010-07-14
WO2004112794A2 (fr)	2004-12-29
EP1638574B1 (fr)	2010-04-14
CA2527703C (fr)	2012-10-23
LUC00055I1 (fr)	2017-12-14
WO2004112794A3 (fr)	2005-06-16
LUC00055I2 (fr)	2018-02-21
CY1110179T1 (el)	2015-01-14
FR17C1063I1 (fr)	2018-02-16
TW200512213A (en)	2005-04-01
SI1638574T1 (sl)	2010-08-31
EP1638574A2 (fr)	2006-03-29
AU2004248909B2 (en)	2008-05-08
BRPI0411563B1 (pt)	2019-09-24
HK1095519A1 (zh)	2007-05-11
CN101164539A (zh)	2008-04-23
ATE464052T1 (de)	2010-04-15
NL300917I2 (nl)	2018-01-09
CY2017048I1 (el)	2018-09-05
DK1638574T3 (da)	2010-08-02
CN100457111C (zh)	2009-02-04
TWI324604B (en)	2010-05-11
LUC00055I9 (fr)	2022-11-09
AU2004248909A1 (en)	2004-12-29
PL1638574T3 (pl)	2010-09-30
BRPI0411563A (pt)	2006-08-01
HUS000503I2 (hu)	2021-03-29
CA2785950A1 (fr)	2004-12-29
US20130289018A1 (en)	2013-10-31
ES2344700T3 (es)	2010-09-03
MXPA05013722A (es)	2006-03-08
CA2527703A1 (fr)	2004-12-29
US20070299049A1 (en)	2007-12-27
NL300917I1 (nl)	2017-12-12
DE602004026578D1 (de)	2010-05-27

Publication	Publication Date	Title
FR17C1063I1 (fr)	2018-02-16
DK1611088T3 (da)	2009-10-19	Hydroxymater som terapeutiske midler
EA200971053A1 (ru)	2010-06-30	Способы лечения кожных язв
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA201390353A1 (ru)	2013-08-30	Производное пиразолохинолина
WO2000064441A3 (fr)	2001-06-14	Medicament
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE520668T1 (de)	2011-09-15	Sigmarezeptor-inhibitoren
PL1656348T3 (pl)	2007-07-31	Pochodne acetylenu jako inhibitory deacetylazy histonowej
TNSN04203A1 (en)	2007-03-12	Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2008070010A3 (fr)	2008-07-24	Rétablissement après une attaque
MXPA06014182A (es)	2007-06-25	Nucleosidos de 3-??-d-ribofuranosiltiazolo[4,5-d]piridimina y usos de los mismos.
GB2427405A (en)	2006-12-27	Novel hydroxamates as therapeutic agents
WO2000076500A8 (fr)	2001-08-16	Compound for use as a medicament for treatment of disorders involving bronchocontraction
TH401002069A (th)	2019-05-10	การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน
RU2006126471A (ru)	2008-01-27	Способ лечения воспалительных заболеваний слюнных желез
SE0103539D0 (sv)	2001-10-23	New Use